• Home >>
  • Pharmaceuticals and Healthcare >>
  • Ophthalmic Drug Market: Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis And Competitive Analysis 2017 - 2025

Ophthalmic Drug Market: Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis And Competitive Analysis 2017 - 2025

ID: 240341 21st May, 2018 Region : Global Pages Reports Monitor

Ophthalmic Drugs Market Research Report: by Indication (Glaucoma, Retinal Disorder, Others), by class (Anti-allergy, Anti-Inflammatory, and Others), by dosage (Eye Drops, Others), by product (Prescription, OTC Drug), by distribution Channel – Global Forecast Till 2025


Ophthalmic diseases such as cataract, glaucoma are spreading at alarming rate. Many times these diseases leads to blindness. Ophthalmic drugs are used to treat these diseases.


The rising prevalence of eye diseases is the key driving force of growing ophthalmic drug market. According to World Health Organization (WHO), around 253 million people are living with vision impairment, out of which 36 million are blind and nearly 217 million have moderate to severe vision impairment. Also, cataract is responsible for 51% of world blindness, which represents about 20 million people (2010). Various other factors such as growing awareness among people about eye diseases and increasing funding by government in research & development of ophthalmology are also helping the market to grow. Additionally, the growing geriatric population and upsurge in healthcare expenditure are dominant drivers for the growth of ophthalmic drugs market.


However, the side effects associated with the ophthalmic drugs and high cost of diagnosing the eye diseases are the major hindrance to the growth of market. Apart from these, poor reimbursement policies and lack of proper healthcare facilities in rural and sub urban areas also hamper the growth of the market.


But, with advancement in technology and growing population the market is expected to have a swift growth. Also, with increasing  diabetic patients and people getting addicted to cigarette & alcohol at young age will increase the number of patient with eye disease. Moreover, increase in investment by market players in emerging economies offers lucrative opportunities for market growth in near future.


Market Segmentation:

The global ophthalmic drugs market is segmented on the basis of indication, drug class, type of dosage, product, and distribution channel.


Based on indication, the market is classified as glaucoma, retinal disorders, inflammation/infection, dry eye, allergies, uveitis, and others.


On the basis of drug class, the market is classified as antiallergy, anti-VEGF agents, anti-inflammatory, antiglaucoma, and others. The anti-inflammatory segment is further segmented into nonsteroidal drugs and steroidal drugs. 


As per the  type of dosage, the market is classified as eye drops, eye solutions, ointments, capsules and tablets, and gels.


Based on the product, the market is classified as prescription drugs and over the counter (OTC) drugs.


On the basis of the distribution channel, the market is classified as hospital pharmacies, online pharmacies, drug stores, and others.


Regional Analysis:

The global ophthalmic drug market is regionally segmented into North America, Europe, Asia pacific and LAMEA.


North America has the largest market share owing to the rising prevalence of eye disease, their ability to adopt the inventive technology and presence of key players of the market in the region. According to the glaucoma research foundation, in the United States, more than 120,000 are blind because of glaucoma. This accounts for 9 to 12% of all cases of blindness of U.S.


Europe stands second in terms of market share. The favorable government policies and increasing competition among the players of the market is helping the healthy growth of the market. Apart, from this many global key players are also present in this region.


Asia pacific is expected to have the fastest growth in the forecast period owing to the fact that patient density is the highest of the region. Additionally the expenditure per capita is increasing in the region. Also, the demand for advanced technology and development in healthcare sector will boost the market of this region.


LAMEA region has the least share of market, this is because of lack of awareness and underdeveloped countries in the region. Although, the number of patient with eye disease is huge. The children of the region are also malnourished. However, the market in Middle East is growing at a swift pace as the economy is stable and there is a growing concern about healthcare.


Key players:

The key players in the global ophthalmic drugs market are Actavis Generics, Allergan Plc, Bausch & Lomb Inc., Genentech, Inc., Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Shire Plc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc.


Market Segmentation:


• By indication

o glaucoma

o retinal disorders

o inflammation/infection 

o dry eye 

o allergies

o uveitis

o others


• By dosage

o eye drops

o eye solutions

o ointments

o capsules and tablets

o gels


• By class

o anti-allergy

o anti-VEGF agents 

o anti-inflammatory

 steroidal

 non-steroidal

o anti-glaucoma

o others


• By product

o prescription drugs

o OTC drugs

• By distribution channel

o hospital pharmacies

o online pharmacies

o drug stores

o others.


• By Geography


o North America

 U.S.

 Canada

 Mexico


o Europe

 UK

 Germany

 France

 Italy

 Spain

 Rest of Europe


o Asia-Pacific

 China

 India

 Japan

 South Korea

 Rest of Asia-Pacific


o LAMEA

 Brazil

 Saudi Arabia

 South Africa

 Rest of LAMEA

Research Scope
 The study for Global Ophthalmic drug Market Survey and Trend Research 2018 will provide market size, estimates and forecast based on the following years: 

Historic data: 2015  Base Year Estimate: 2017  Forecast: 2018 to 2025

The report has been categorized in two distinctive sections, where the first category titled as Market Overview provides a holistic view of the market, key trends, drivers, challenges/restraints or opportunities with their current and expected impact on the overall industry sales. 
Our analyst implement, several qualitative tools such as Ansoff’s Matrix, PESTEL analysis, Porter’s five force analysis among other to interpret and represent key industry findings. 
The second section of the study provides market size, estimates and forecast for key market segments and regional market. The final part of the report highlights key manufacturers/vendors operating in the associated market.
 
1. Introduction
1.1. Market Definition
1.2. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Secondary Sources
2.3. Assumptions & Exclusions

3. Market Overview
3.1. Research Report Segmentation & Scope
3.2. Key Market Trend Analysis
3.2.1. Market Drivers
3.2.2. Market Restraint/Challenges
3.2.3. Market Opportunities
3.3. Porter’s Five Forces Analysis
3.4. Potential Venture Avenues
3.5. Market Share Analysis, 2016 

4. Product Overview
4.1. Introduction 
4.2. Market Size & Forecast, 2015 to 2025
4.3. By type
4.3.1. eye drops
4.3.2. eye solutions
4.3.3. ointments
4.3.4. capsules and tablets
4.3.5. gels
(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)

5. Regional Overview
5.1. Introduction
5.2. Market Size & Forecast, 2015 to 2025
5.2.1. North America
5.2.1.1. U.S.
5.2.1.2. Canada
5.2.1.3. Mexico 
5.2.2. Europe
5.2.2.1. UK
5.2.2.2. Germany
5.2.2.3. France
5.2.2.4. Italy 
5.2.2.5. Russia
5.2.2.6. Poland
5.2.7. Rest of Europe
5.2.3. Asia-Pacific
5.2.3.1. China
5.2.3.2. India
5.2.3.3. Japan
5.2.3.4. Australia
5.2.3.5. South Korea
5.2.3.6. Rest of Asia-Pacific
5.2.4. LAMEA
5.2.4.1. Saudi Arabia
5.2.4.2. UAE
5.2.4.3. South Africa
5.2.4.4. Rest of LAMEA
(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)

6. Manufacturer/ Vendor Profile
6.1. The following attributes will be considered while profiling key manufacturers in this industry: 
6.1.1.1. Company Overview
6.1.1.2. Financial Synopsis
6.1.1.3. Recent Developments
6.1.1.4. R&D Investments (if any)
6.1.1.5. Strategy Overview (Analyst Perspective)
6.1.1.6. Product Portfolio
6.2. Companies Profiled
6.2.1. Actavis Generics
6.2.2. Allergan Plc
6.2.3 Bausch & Lomb Inc.
6.2.4. Genentech, Inc.
6.2.5. Merck & Co., Inc.
6.2.6. Pfizer Inc.
6.2.7. Regeneron Pharmaceuticals, Inc.
6.2.8. Santen Pharmaceutical Co., Ltd.
6.2.9. Shire Plc
6.2.10. Sun Pharmaceutical Industries Limited
6.2.11. Teva Pharmaceutical Industries Ltd.
6.2.12. Valeant Pharmaceuticals International, Inc.
(Note: The companies mentioned above are tentative in nature, and profiles of other market players not listed here can be included on request.) 

Request Sample

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Request Discount

Name*

Email*

Phone*

Name of the Company*

Title/ Designation*

Select Country*

How can we help you?

Related Reports




Get 15 minutes of free Consultation When you request a Sample Report!

24/7 Research Report

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone:

+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected]